# TMPRSS2

Source: https://onco.cc/targets/tmprss2/  
OnCo record `tmprss2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TMPRSS2 (Transmembrane protease serine 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.

## Summary

Plasma membrane-anchored serine protease that cleaves at arginine residues. Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate. Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells.

Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.76, literature 0.99, genetic association 0.66, somatic mutation 0.77, animal model 0.28). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Prostate Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: transmembrane serine protease 2; Transmembrane protease serine 2; PRSS10
- Tags: cancer-genes-wave
- Symbol: TMPRSS2
- Class: oncogene
- Biology: Plasma membrane-anchored serine protease that cleaves at arginine residues. Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate. Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells. In addition, activates trigeminal neurons and contribute to both spontaneous pain and mechanical allodynia. The cleavage of SARS-COV2 spike glycoprotein occurs between the S2 and S2' site. Upon SARS-CoV-2 infection, increases syncytia formation by accelerating the fusion process. Location: Cell membrane; Secreted (UniProt). Locus 21q22.3 (HGNC).
- Where found: Prostate cancer: Open Targets association 0.72 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11876: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11876
- UniProt O15393: https://www.uniprot.org/uniprotkb/O15393/entry
- NCBI Gene 7113: https://www.ncbi.nlm.nih.gov/gene/7113
- Ensembl ENSG00000184012: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184012

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- key papers: [Integrative genomic profiling of human prostate cancer](https://onco.cc/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/), [Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours](https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/), [Punctuated evolution of prostate cancer genomes](https://onco.cc/key-papers/paper-baca-punctuated-evolution-chromoplexy-cell-2013/), [Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer](https://onco.cc/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/), [TCGA: the molecular taxonomy of primary prostate cancer](https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/), [The mutational landscape of lethal castration-resistant prostate cancer](https://onco.cc/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/), [The TMPRSS2-ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and meta-analysis](https://onco.cc/key-papers/paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012/), [Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression](https://onco.cc/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/)
- terms: [Chromoplexy](https://onco.cc/terms/chromoplexy/)
- biomarkers: [TMPRSS2-ERG fusion (and the other ETS rearrangements)](https://onco.cc/biomarkers/tmprss2-erg-fusion/)

---
JSON: https://onco.cc/api/v1/entities/tmprss2.json